Fig. 5
Forest plot for the meta-analysis of the outcome safety demonstrating non statistically significant effect of polymorphisms of cytochrome P450 on the risk to develop bradycardia after treatment with timolol (OR 6.15 [0.37–103.45], P = 0.21). Only three studies with high heterogeneity (I2 = 94%; P < 0.00001) investigated this outcome